Study Of Adriamycin Albumin Nanoparticles In The Interventional Treatment Of Hepatocellular Carcinoma

Nanoparticles as drug carriers possess the characteristics of being tiny particles,having relatively big surface area and good adhesion.They easily cross the walls of blood vessels to enter target tissue and increase the contact time and contact area of drugs with tumors.As their surface area is greater,dissolution is better.Nanoparticles as drug carriers can improve the bioavailability of drugs.Thus,they can improve therapeutic effect and decrease costs.The volume of nanoparticle carrier is ultra small and can directly act on cells.By controlling the continuous gradual release of drugs onto target genes,the response time can be effectively prolonged,effective concentration can be maintained,the efficiency of gene transfer can be increased and the bioavailability of gene transfer products can be improved.While maintaining therapeutic effectiveness, drug dosage can be reduced,toxic side-effects can be decreased or avoided,the stability of drugs and genes can be increased and a relatively high concentration can be created locally.Studies found that in an externally applied magnetic field,over 60% of magnetic doxorubicin albumin nanoparticles were distributed in animal liver,liver cancer was greatly inhibited and the survival time of the animal was increased.However,the strength and positioning of the externally applied magnetic field is difficult to control and there is some application limitation.How to choose a precise and accurate method of transport of nanoparticIe drugs to the target as therapy has always been a field for research.After 20 years of development,interventional therapy has already become a third treatment option apart from medical and surgical therapies. Among the therapies,selective hepatic artery chemoembolization as a main interventional technique has already become the treatment of choice for nonsurgical treatment of liver cancer.However,interventional therapy is far from ideal.How to improve its methods and increase survival rate of patients is an important research topic in interventional therapy.Our study uses albumin nanoparticles as drug carriers,which combines with doxorubicin anticancer drug to obtain doxorubicin albumin nanoparticles.Through an interventional technique,nanoparticle drugs are directly sent into arteries supplying the liver cancer as cancer treatment.Using a combination of nanobiotechnology and interventional treatment techniques,our objective is to improve the effectiveness of liver cancer therapy.Details of the study comprise of:1.research of the preparation and characteristics doxorubicin albumin nanoparticles;2.doxorubicin albumin nanoparticles biocompatibility 3.Pharmacokinetics of adriamicin albumin nanoparticles4.interventional treatment of liver cancer with adriamicin albumin nanoparticlesThe research in the properties and preparation of doxorubicin albumin nanoparticles has attained the intravenous drug standard for adriamicin albumin drug carrier nanoparticles.The average diameter of the particle is 201±26 nm,amount of drug carried 53.62±5.34μg/mg, encapsulation percentage of 96.61±3.73%,recovery rate of 99.55±1.62%,and in vitro release experiments showed that adriamicin drug cartier nanoparticles had good slow release properties.Biocompatibility of adriamicin albumin nanoparticles showed that the nanoparticle carrier was not toxic,had no bacteriostatic,no hemolytic, no pyrogenic and no skin irritation effects.Wound healing was good in long-term intramuscular implantation animal studies.Tissue reaction was small.This showed that the material had good cellular and tissue compatibility.Adriamicin albumin nanoparticle pharmokinetics studies confirmed that in average serum drug levels-time curve,decrease in albumin adriamicin nanoparticle gradient is more than that of adriamicin. Adriamicin albumin nanoparticle serum levels were maintained for a relatively longer period at a relatively stable concentration of 0.0778±0.0015 mg/L,and adriamicin serum level showed a gradual decreasing tendency.Also,adriamicin albumin nanoparticle clearance is 0.5369 times that of adriamicin.The area under curve(AUC)of albumin adriamicin nanoparticle serum concentration-time curve is 1.3679 times that of adriamicin.In the study of the preparation of adriamicin albumin nanoparticle, based on biocompatibility and pharmacokinetics,we explored further using interventional technique the therapeutic effect of adriamicin albumin nanoparticle in rabbits transplanted with human liver cancer. Results showed that in the free adriamicin(B group)and adriamicin albumin nanoparticle(C group)groups,tumor growth was significantly decreased(P＜0.01),but there also was significant statistical difference between B and C groups when compared(P＜0.05).The average survival period of the control group(A group)was 27 days,38 days for B group and 54 days for C group.Statistical analysis showed that when comparing B and C groups with A group,survival period was greatly increased. (P＜0.01),with longest period noted in C group,even longer than in B group(P＜0.01).Through our research,we believe that adriamicin albumin nanoparticle is safe,nontoxic,non-pyrogenic and has good cellular and tissue compatibility.It also has great gradual release property and meets anticancer drug nanoparticle carrier requirements.By using interventional technique,adriamicin albumin nanoparticle can be accurately released at target sites and improving liver cancer therapy.Using the interventional technique as basis,our study can be applied to the research of other gene drags and therapy of other malignant tumors.